Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...

ASML extends losses after cutting sales guidance, Nvidia stock edges higher, and third-quarter earnings at Morgan Stanley top ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat ...

Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...

Fintel reports that on October 16, 2024, HC Wainwright & Co. upgraded their outlook for NovoCure (NasdaqGS:NVCR) from Neutral ...

NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in ...

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small cell lung cancer—which the company described as the first treatment ...

On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment, which resulted in positive price action. The lung cancer market will significantly increase NovoCure's scale ...

Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target ...

Piper Sandler analyst Jason Bednar maintained a Buy rating on NovoCure (NVCR – Research Report) today and set a price target of $28.00.